NCT04722471

Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 347 (actual)
• Sponsor: Instituto Bernabeu · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This study aims to compare the efficacy, in terms of progesterone levels and clinical outcomes, of two different presentations of micronized vaginal progesterone (400 mg vs. 200 mg) used in endometrial preparation in artificial cycle (AC) for embryo transfer. This is a non-inferiority, retrospective case-control study, with at least 200 cycles analyzed (at least 100 per arm) and the primary outcome is the serum progesterone level on the day of the embryo transfer.

Conditions

• Luteal Phase Defect

Interventions

Type	Name	Description
DRUG	Vaginally administered progesterone	The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)

Timeline

• Start date: 2021-03-03
• Primary completion: 2021-03-03
• Completion: 2021-03-17
• First posted: 2021-01-25
• Last updated: 2021-03-19

Locations

1 site across 1 country: Spain